Form 4: Cerus CMO Sells Shares for Tax Obligations

Cerus's Chief Medical Officer, Richard J. Benjamin, sold 101,740 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Richard J. Benjamin, Chief Medical Officer of Cerus Corp (CERS), reported a sale of 101,740 shares of common stock.
• The transaction occurred on March 12, 2026, at a weighted average price of $1.6572 per share.
• The sale was non-discretionary, executed under a Rule 10b5-1 plan, specifically to cover statutory tax withholding obligations and brokerage fees associated with the vesting of restricted stock units.
• Following this transaction, Mr. Benjamin beneficially owns 777,361 shares of Cerus common stock.
• The shares were sold in multiple transactions with prices ranging from $1.62 to $1.73 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a non-discretionary sale to cover tax obligations related to RSU vesting, which is a routine part of executive compensation and does not reflect a change in the insider's investment sentiment.

Future Outlook

This filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale represents shares sold pursuant to an instruction intended to comply with Rule 10b5-1, elected by the Reporting Person on the date of grant.
• The purpose of the sale was to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units.
• The sale does not represent a discretionary sale by the reporting person.

Industry Context

StockSavvy.ai notes that sales of company stock by executives to cover tax obligations upon the vesting of restricted stock units (RSUs) are a common and routine occurrence across industries. These transactions are typically pre-arranged under Rule 10b5-1 plans and are not usually indicative of an executive's sentiment about the company's future prospects.

Comparison to Industry Standards

• This type of non-discretionary sale for tax purposes is a standard practice for executives receiving equity compensation, aligning with common compensation structures seen in biotech and other high-growth sectors.
• Similar transactions are frequently observed at companies like Gilead Sciences (GILD) or Amgen (AMGN) when executives' restricted stock units vest, where a portion of the shares are automatically sold to satisfy tax liabilities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in company fundamentals or insider sentiment.

Key Dates

Keywords

CERS, Cerus, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Rule 10b5-1